Found: 3
Select item for more details and to access through your institution.
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266392
- By:
- Publication type:
- Article
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 386, doi. 10.2967/jnumed.123.266392
- By:
- Publication type:
- Article
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.266392
- By:
- Publication type:
- Article